Navigation Links
Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival

and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to c
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting

Post Your Comments:
(Date:11/7/2009)... Fla., Nov. 7 Patients reported C1...ective therapy in treating acute swelling attacks ...enetic disorder, according to data presented today...amp; Immunology (ACAAI) Annual Meeting. The result...ducted in parallel with the ongoing, prospective, ...
(Date:11/6/2009)...h., Nov. 6 SCOLR Pharma,...ts for the three and nine months ended September 3... President and CEO, said, "We continue to advance ...ofen formulation. Several potential partners have ... and external resources as they evaluate the poten...
(Date:11/6/2009)...ov. 6 Recession in domes... sales for Allied Healthcare Products in the first...2009. ,, Sales declines pushed Allied into a lo...was about $745,000, or negative 9 cents per share,...t $208,000, or 3 cents per share. ,, Sales fel...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 1Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 2Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 1Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 2Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 3Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 4Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 5Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 1Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 3
...y 10, 2007 /PRNewswire/ --,Pieris AG, a bio-pharma... class of targeted human protein therapeutics, tod...vel, effective products for,the potential treatmen... Anticalin(R) candidate, the Company reports that ...rget of action via,the lungs. , PRS-060 has been s...
...st for meeting with FDA, SEATTLE, July 11, 2007 /P...TI) announced today that interim results of,its ph...rone is,substituted for doxorubicin in standard CH...ive non-Hodgkin,s lymphoma (NHL), resulted,in esse...r,objective anti-tumor response (complete response...
Other Medicine Technology:Pieris Progresses Proprietary Asthma Program: Validation of,Pulmonary Delivery of Anticalin-Based Protein Product Candidate 2Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 2Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 3Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 4Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 5
(Date:11/8/2009)... Passage of H.R. 3961 to Secure the Stability of M...ire/ -- Statement Attributable to: J. James Rohack..., (Logo: http://www.newscom.com/cgi-bin/prnh/...age of the House health reform bill, which will he...icians and calls for swift passage of H.R. 3961 to...
(Date:11/8/2009)...e Shows Who Sides With Working Families vs. Insura...wswire-USNewswire/ -- On the heels of an historic ...r a good, balanced health care reform bill, the Pe... state,s U.S. representatives voted on HR 3962, th...he legislation, which passed Saturday evening by a...
(Date:11/7/2009)... 7 Karen Ignagni, Presi...AHIP), released the following statement today on H...ongly support comprehensive health care reform, an...ing a complete overhaul of how health insurance is...ed coverage, elimination of pre-existing condition...
(Date:11/7/2009)... The American Medical As...ctor of Health at the Family Violence Prevention F...oday at its semi-annual policy-making meeting. Th...t honor the AMA House of Delegates bestows on a no...com/cgi-bin/prnh/20081209/AMALOGO ) ,, "Ms. J...
(Date:11/7/2009)... Members of the AMA are ...ncy resolution rescinding the AMA,s support of HR ...ey are responsible to their PATIENTS, not the lead...of Policy for the Association of American Physicia...on of other medical groups. ,, "If the AMA lea...
Breaking Medicine News(10 mins):Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
...e "Extremely Affordable Health Innovations" Poste...al World Health Care Congress with support from Gr...ive organizations involved in developing or implem...eloped, or are in the process of developing, to th...
...EIGH, N.C., March 13 North Carolina students inte...re encouraged to attend the 2009 Optometry Career ...th Carolina and the N.C. State Education Assistanc...0:00 a.m. - 12:00 noon, Tuesday, March 24, 2009 in...
...CSF Medical Center has received a $125 million gif...specialty and cancer hospital complex at the UCSF ...his is the largest support to date for the $600 mi...t from other philanthropists, was made by Charles ...
...hanging physician behaviors forecast print news de... FALLS, N.J., March 13 , , Background : The...nsizing of many U.S. newspapers just a day after ...rk Times reports that three papers are ceasing t...
... HARBIN, China, March 13 /PRNewswire-Asia/ -- Chin...r "the Company") (Nasdaq: CSKI ), a leading full...-the-counter drugs in the,People,s Republic of Chi...e Conference in Shanghai and The World Money Show ...
...vista HPV HR: First FDA approved high-risk HPV tes...NA genotyping test approved by the FDA , , BEDFOR... Company) (Nasdaq: HOLX ), a leading women,s hea...Company,s premarket approval (PMA) applications fo...
Other Medicine News:Health News:Extremely affordable health innovations at World Health Care Congress, April 14-16, Washington 2Health News:Extremely affordable health innovations at World Health Care Congress, April 14-16, Washington 3Health News:Optometry Career Conferences Set for Five N.C. Campuses in March 2Health News:UCSF Medical Center receives $125 million gift to build new hospital 2Health News:UCSF Medical Center receives $125 million gift to build new hospital 3Health News:UCSF Medical Center receives $125 million gift to build new hospital 4Health News:Print Media Under Siege - Are Readers Disappearing? 2Health News:China Sky One Medical to Attend Two Conferences in March 2Health News:China Sky One Medical to Attend Two Conferences in March 3Health News:FDA Approves Two Hologic HPV Tests 2Health News:FDA Approves Two Hologic HPV Tests 3Health News:FDA Approves Two Hologic HPV Tests 4
Topcon OM-4 Ophthalmometer
...gital chip technology, the new IMAGEnet 2000 Super...res 3,072 x 2,048 pixels resolution and a 12-bit d...ovides exceptionally sharp and detailed images. It...facilitates instant diagnosis by allowing the inst...
Topcon TLS-FD trial lens set
AIT-15 instrument table
Medicine Products: